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invading pathogen. The systemic inflammatory responseTreatment of sepsis is still a major issue for our health care
system and morbidity and mortality among patients are very
high. Treatment options of septic patients are scarce and have
not changed dramatically over the past three decades. These
strategies rely predominately on the right choice as well as the
timely application of broad-spectrum antibiotics, hemody-
namic resuscitation and support of organ function if neces-
sary [1]. However, to date many bacterial strains resistant to
certain antibiotics emerge as imminent problems in our
health care system. Therefore, there is a dire need for new
therapeutics eliminating the primary ‘threat’ as well as mod-
ulating the host immune response. Unfortunately immune
suppressive treatment of septic patients with ‘biologicals’
targeting proinflammatory molecules such as TNFa as well
as procoagulant molecules such as tissue factor proved to be
ineffective and failed with only a few exceptions. The devel-
opment of these ‘biologicals’ based on initial studies
mostly in the 1990s using different animal models of sepsis.Unfortunately although most of those agents showed pro-
mising results in animal studies either the choice of the
model or species differences precluded successful trials in
human patients.
Sepsis
Sepsis is clearly defined by a systemic host response to an
syndrome (SIRS) may also be induced by other noninfectious
insults such as burns and trauma. Sepsis is further character-
ized by clinical signs of hyperthermia or hypothermia, tachy-
cardia, tachypnea, leukocytosis or leukocytopenia [2].
Concomitantly the compensatory anti-inflammatory
response syndrome (CARS) is initiated to limit the inflam-
matory response and protect the host from excessive inflam-
matory tissue damage. Sepsis is a multifaceted disease
syndrome with a multitude of factors and parameters
involved and therefore the disease is still barely understood.
Homeostasis of proinflammatory as well as counter-acting
anti-inflammatory mechanisms is mandatory to prevent the
dysfunction of host organs such as lung, liver or kidney.
Moreover it is important to categorize patients to develop
personalized treatment strategies. In some immune-sup-
pressed patients the initial infection cannot be contained,
spreads and causes sepsis. In another group of patients the
host inflammatory response is exacerbated, continues and
becomes dysregulated leading to SIRS, sepsis and subse-
quently septic shock. This course of the disease results inod.2011.10.002 e17
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[1]. The initial triggering cause of the disease may be multi-
faceted. The majority of the septic complications are due to
various bacterial infections. However, alternative but less
frequent causes for sepsis are viruses, fungi and other para-
sites. The pathogens may enter the host via different body
surfaces due to dysfunctional barrier protection. Among
those the lungs as well as the intestines are commonly found
entry routes. Influx of bacteria into the peritoneal cavity after
leakage of the intestines due to disease, trauma or surgery
leads to peritonitis, which may result in sepsis [3]. Therefore
different animal models such as ‘cecal ligation and puncture
(CLP)’ and ‘colon ascendens stent peritonitis (CASP)’ mimick-
ing this type of disease progression have been developed
during the past 30 years.
Cecal ligation and puncture
The CLP murine model of peritoneal, polymicrobial sepsis is
the so-called ‘gold standard model’. It has been widely used
over the past 30 years to study the pathobiology of sepsis
[4,5]. CLP was developed among others by the group of
Chaudry in the 1970s [5]. In PubMed more than 1600 hits
for ‘cecal ligation puncture AND sepsis’ are found. CLP has
several advantages to offer. It requires a simple experimental
procedure, which is represented by polymicrobial infection of
the peritoneum with a localized infectious focus. Further-
more, bacteria as well as pathogen associated molecular
patterns (PAMPs) are released into the host periphery. Taken
together this will eventually lead to septicaemia at later stages
of the disease. In recent publications the model has been
described together with an educative video [6,7].
In short the procedure to induce CLP in mice is character-
ized by midline laparatomy, the cecum is prepared and
ligated directly located below the ileocecal valve (Fig. 1). This
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Figure 1. Schematic representation of cecal ligation and puncture
model. CLP is induced by isolation, ligation and puncture of the cecum
right below ileocecal valve. The location of the ligation and the type of
puncture determine the severity of the disease model. Sham
operation is performed by isolation of the cecum without ligation and
puncture.
Modified from Ref. [23].
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[8]. Cecal ligation is followed by the puncture of the cecum by
a defined needle size.
The severity of peritonitis can be increased by a thorough
through and through puncture. Moreover, the cecum may be
punctured more than once. Wound patency is warranted in
order that feces can leak into the peritoneal cavity. In theory
needle size as well as the number of punctures define the
severity of the disease [5]. However, there is conflicting data
in the literature on that matter claiming that needle size as
well numbers of punctures do not alter the severity of the
model [9]. At later stages of CLP the disease is irreversible. This
is shown by the late excision of the ligated cecum, which did
not prevent mortality of mice in the model [10,11]. Interest-
ingly, necrotic tissue of the ligated cecum does not interfere
with innate immune functions of the animal. A recent study
could show that the fecal content, in a TLR4 independent
manner, but not the necrotic tissue causes impaired bacterial
clearance upon secondary infection with Pseudomonas [12].
CLP shows only transient bacterial dissemination in the
peritoneal cavity and in particular other organs [13,14].
Therefore, septicemia is not as pronounced as in the CASP
model but may be detected at later stages of the disease [9,15].
Several important inflammatory molecules have been
shown to be indispensable for CLP peritonitis. For instance,
TNFa plays a pivotal role in the development of this disease
model [13,14]. Downstream of PAMP recognition the
release of cytokines is required to mount the host defence
against the CLP-induced bacterial infection. However, the
important cytokine IL6 shows conflicting results in this
respect. On one hand IL6 is required for survival in experi-
mental sepsis models using Listeria and Klebsiella [16,17]. By
contrast IL6 is an essential molecule in the pathobiology of
tissue or organ damage in the CLP model. Blockade of IL6
using antibodies increased the survival of septic mice. In
addition reduction of complement activation as well as
neutrophil depletion leading to reduced IL6 levels also
protected the animals in the CLP model [18,19]. Another
example for an essential innate immune cascade which is
involved in host defence that has been analyzed using CLP
is the complement system. The complement system is an
important antibacterial as well as proinflammatory protease
cascade. Blockade of the complement factor C5a or the C5a
receptor leads to organ protection and increased survival in
the CLP model [20–22]. Taken together it can be summar-
ized that the CLP has been extensively used to study mole-
cules that have been implicated in the host immune
reactions to bacterial infection.
More recently a second murine peritoneal sepsis model has
been developed, namely the CASP. Although it has been
developed to circumvent some of the flaws of the CLP model
such as reproducibility, it turned out to be entirely different
in terms of pathogenesis and disease progression.
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The CASP model of peritoneal, polymicrobial sepsis is not as
commonly used as CLP. Only in recent years this model
began to replace or rather complement the ‘gold standard
model’ CLP. In PubMed less than 100 articles containing
(colon ascendens stent AND sepsis) can be found. This clearly
indicates that the scientific community still heavily relies on
CLP to model peritoneal sepsis. The CASP model was first
introduced as an alternative sepsis model in 1997/98 by Zantl
et al. [23]. Recently the model has been thoroughly described
including an interesting as well as educative video [24].
In short the procedure to induce CASP is characterized by
the fixed insertion of a stent (catheter) into the colon ascen-
dens by laparotomy (Fig. 2). Fecal content is milked from the
cecum into the stent and finally may leak from the stent into
the peritoneal cavity, which leads to polymicrobial peritoni-
tis and subsequently sepsis [24]. The severity of the disease is
defined by the diameter of the stent ranging from 14 gauge
(100% lethality) to 20 gauge (50 or less % lethality).
As mentioned above all of the mice with an implanted 14G
catheter succumbed to the disease and died within the first
48 hourspostsurgery [9]. Interestingly themodel systemcan be
modified by removing the stent after a certain period of time to
mimic surgical intervention in patients with the aim to elim-
inate the sourceof infection.However, ithas beenshown thata
particular time interval postsurgery the removal does not
improve survival (approx. nine hours). This has been shown







Fig. 2. Schematic representation of the colon ascendens stent peritonitis model
right next to the cecum. Sham operation is performed by fixing the catheter to t
CASP induction (less than nine hours).
Modified from Ref. [23].late excision of the ligated and necrotic cecum, which even-
tually did not rescue CLP mice from death.
In contrast to CLP, CASP does not seem to strictly rely on
TNFa secretion [23]. The CASP model strongly depends on
the activation of the innate immune system via TLRs, in
particular TLR2 and TLR4. In addition the activation of the
TLR adaptor molecule MyD88 is important for the develop-
ment of sepsis induced by the CASP model [25]. In a more
recent study administration of a single bolus of an inhibitory
anti-TLR4/MD2 antibody could prevent CASP induced death
[26]. Among the inflammatory cytokines and bactericidal
molecules implicated in sepsis IL12 and inducible nitrogen
monooxide synthase (iNOS) have been studied using the
CASP model. Gene deficiency for IL12 as well as iNOS ren-
dered mice more susceptible to CASP peritonitis underscoring
the importance of these molecules in the antibacterial
immune defence [27]. Downstream of bacterial recognition
and the initial inflammatory response by immune competent
cells, activation of the complement system is also important
in CASP. Administration of exogenous complement factor C3
protected mice from lethality (or symptoms) of CASP induced
sepsis [28]. The coagulation cascade and associated antic-
oagulation molecules have been shown to be important in
inflammatory as well as infectious diseases. One of those
molecules, the activated protein C (aPC), which not only
terminates the coagulation cascade but also has interesting
cytoprotective features, is already in clinical use for the





. CASP is induced by the fixed insertion of a stent into the ascending colon
he intact intestinal wall. CASPI is defined by the removal of the stent after
www.drugdiscoverytoday.com e19
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gulatory but normal cytoprotective and anti-inflammatory
properties could significantly prolong the survival of CASP
mice [29]. This finding might be useful for septic patients,
because common side effects of treatment with recombinant
aPC are serious bleeding complications. Taken together this
clearly shows that CASP is an important model to mimic
human sepsis. However, the scientific community is still not
convinced in the regular use of it.
Model comparison
Possible flaws of CLP and CASP sepsis models
One of the most important issues applying the CLP or the
CASP model is the high variability among the animals
included in a particular study. Experimental variability
may obscure a hidden phenotype. However, published data
indicate that the CASP model is more reliable than CLP in this
respect [9]. High n-numbers are needed for both CLP and
CASP to achieve certainty whether the observed effect is
based on a real phenomenon. First and foremost the animals
selected for a particular experiment must be housed under the
very same conditions for an extended period of time (at least
one week). Littermate controlled experiments are preferred.
In addition, reasons for inter-animal differences may be the
experimental handling of mice and surgical expertise of the
experimenter. Another possibility might be simple anatomi-
cal differences among animals. For instance the cecum even
of inbred littermate mice may be different in size or fill level.
However, the size of the ligated cecum determines the degree
of severity of sepsis. This is very important to consider for the
CLP model. The fecal content, the condition as well as the
actual amount of stool present in the cecum can vary quite a
bit. The same is true for the colon to a certain extent for the
CASP model. Similarly differences, in the fecal material that
leaks out either the puncture (CLP) or the stent (CASP) might
account for additional inter-animal variability.Table 1. Characteristics of animal models of peritonial sepsis.
Cecal ligation and puncture (CLP)
Pros - Easy procedure
- Less time consuming
- Analysis of inflammatory cell recruitment
- Partly reflects human disease
Cons - Invariability
- High n-numbers required
- Restriction to the peritoneum and invariable
bacterial dissemination
- Necrosis of the cecum
Best use of model Study of peritoneal abscess formation accompan
by local peritoneal infection, inflammation and in
e20 www.drugdiscoverytoday.comCLP versus CASP
Both models do have several advantages as well as disadvan-
tages (Table 1).
As pointed out CLP and CASP are diverse models covering
different aspects of sepsis. The response of the host to the CLP
model is the attempt to fend off the infection by walling off
the source of infection. This abscess formation has often been
observed in CLP [5,9]. By contrast the CASP model is clearly a
model for polymicrobial peritonitis with bacteremia detect-
able as early as 12 h postsurgery. Systemic and circulating
levels of cytokines and chemokine such as TNF, IL-1, IL-12,
IL18, IFNg, KC/GRO-a and MCP-1 are observed within a short
period of time (three hours) after stent implantation. But not
only proinflammatory cytokines indicative of SIRS are pre-
sent early on. Also anti-inflammatory IL10, which is a sign of
CARS is expressed after three hours post-CASP induction
[15,30].
These differences between the two models have been
shown for several various gene-deficient mouse strains that
have been subjected either to CLP or CASP. These published
data show contrary results for different important molecules
involved in the murine innate inflammatory response to
infection. TNFa deficient mice are protected in CLP, whereas
TNFRp55/TNFR1 deficient show no difference as compared to
wildtype mice in the CASP model [14,23]. Although several
reviews point that out, one has to be careful with that
assumption, because only one TNFR is eliminated. Appar-
ently there is a distinct phenotype of TNFR1 (mediates TNFa
cytotoxic effects) and TNFR2 (protective) deficient mice, at
least when subjected to CLP [31]. The opposite has been
found for IFNg and IFNg receptor deficient mice in the
CLP and CASP model [23,32]. Similarly deficiency of the
important innate immune cytokine IL12p40 results in higher
susceptibility to the CASP model [27]. By contrast no signifi-
cant effects have been found when using the CLP model [32].
In this respect one has to mention distinct results thatColon ascendens stent peritonitis (CASP)
- Analysis of bacteremia and sepsis development
- Analysis of SIRS
- Partly reflects human disease
- Similar disease staging as compared to humans
- Invariability (less than CLP)
- High n-numbers required





Study enterobacterial peritoneal infection
accompanied by bacteremia, SIRS and sepsis progression
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A more recent paper using IL12p40 deficient mice in sub-
lethal CLP provide evidence that these mice are more suscep-
tible to CLP-induced sepsis [33].
Comparison of some of the key players in the innate
immune defence revealed that there are specific differences
in the outcome which may be attributed to the model of
choice. However, still some of the discrepancies found in the
literature are not due to the CLP or the CASP model. The
precise reproducible experimental setup is of utmost impor-
tance to achieve comparable data sets in different labora-
tories.
Conclusion
Animal models of acute inflammation and infectious dis-
eases, especially in rodents, have long been used to study
and understand the pathophysiology of human sepsis.
Furthermore a great number of therapeutics has been eval-
uated in studies using animal models of sepsis. To date only a
limited number of those studies have proven to be translated
successfully from the murine model to the treatment of
human patients in the clinic. In many of those disappointing
failures the wrong choice of the model precluded successful
trials. In the meantime models such as CLP and CASP have
been used extensively. These models are better characterized
by now and quite a bit of knowledge on the parameters
involved have been accumulated over the past ten years of
research. They offer the opportunity to re-evaluate some of
the treatment strategies (most of those failed) that have been
developed some years ago.
However, it is clear that sepsis is a disease covering a
multitude of immunologic, inflammatory as well as coagu-
latory aspects (and many others not even mentioned in this
review). It shows a multifactorial disease pattern, which
implies multifactorial therapy. To study these combinations
of possible treatment options in vivo, CLP as well as CASP offer
advantages to analyze different aspects of sepsis.
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